Form 4: Director Timothy Coughlin Trades ADC Therapeutics Shares

Director Timothy Coughlin of ADC Therapeutics SA reported transactions involving common shares and restricted stock units.

Summary

• Timothy Coughlin, a Director at ADC Therapeutics SA, reported a grant of 45,000 restricted stock units (RSUs) on June 1, 2026, with a value of $0, which are subject to vesting conditions.
• On June 3, 2026, 12,600 common shares were withheld to cover tax obligations related to the vesting of previously granted restricted share units.
• Following these transactions, Coughlin beneficially owns 72,400 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions and compensation disclosures rather than significant strategic or financial performance indicators.

Positives

• Director Coughlin received an annual grant of restricted stock units, indicating continued incentive for service.
• The company is utilizing a standard mechanism (share withholding) to manage tax liabilities associated with equity awards.

Negatives

• A portion of vested equity awards (12,600 shares) was used to cover tax obligations, reducing the net shares received by the director.

Risks

• The vesting of RSUs is contingent upon continued service to the Issuer, implying a risk of forfeiture if service is terminated before vesting.
• The value of the RSUs is subject to market fluctuations of ADC Therapeutics SA's common stock.

Future Outlook

The restricted stock units granted on June 1, 2026, are set to vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, contingent upon the reporting person's continued service.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders and reflect standard compensation practices within the biotechnology and pharmaceutical sectors, where equity incentives are common for directors and executives.

Stakeholder Impact

• Shareholders: The filing provides transparency into director compensation and beneficial ownership, which is a standard aspect of corporate governance.
• Employees: The use of equity incentives like RSUs is a common practice that can align employee and executive interests with shareholder value.
• Management: The transactions reflect the ongoing compensation structure for directors.

Next Steps

• Vesting of the 45,000 RSUs on the earlier of June 1, 2027, or the 2027 Annual Meeting of Shareholders, subject to continued service.
• Potential future tax withholding events upon vesting of equity awards.

Key Dates

Keywords

Form 4, SEC Filing, ADC Therapeutics SA, ADCT, Director, Restricted Stock Units, RSUs, Beneficial Ownership, Equity Incentive Plan, Stock Transactions, Tax Withholding